Annovis Bio Inc (ANVS) Stock Price, Quote & News

Company Profile

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 2/3 to treat alzheimer's disease, as well as in phase 3 to treat parkinson's disease; and is in phase 2 clinical trial to treat lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phas...

Industry: Biotechnology

Sector: Healthcare

Phone: 484 875 3192

Website: www.annovisbio.com

Address:

101 Lindenwood Drive, Suite 225, Malvern, United States

zshortcut Feb. 17 at 4:23 PM

$ANVS so what are we radio silence till 2027 now?

1 · Reply

RiskRecon Feb. 17 at 3:49 PM

$ANVS Annovis Bio develops Alzheimer's and Parkinson's therapies, with clinical-stage pipeline and binary catalysts.

0 · Reply

Veni_Vidi_Vici Feb. 17 at 2:07 PM

$ANVS I am no expert. Do your own due diligence. Understand the risks before investing in a clinical stage biotech. Annovis Followers on Stocktwits = 9,762

1 · Reply

Madsj79 Feb. 17 at 6:57 AM

$ANVS p-tau217 is a breakthrough blood test for risk of developing Alzheimer's disease. Important to know there are sex differences for this biomarker, with women having higher values at baseline and more tau deposition. @JAMANeuro http://jamanetwork.com/journals/jaman… The p-tau217 breakthrough is a game-changer for ANVS, offering a low-cost, precise way to prove Buntanetap’s efficacy. Using this biomarker in the PDD study allows Maria to target high-risk patients—especially women—while providing the objective data the FDA requires. It transforms the trial into precision medicine, simplifies bridging data from the AD study, and creates a faster, more credible path to approval.

1 · Reply

junkjar291 Feb. 17 at 4:12 AM

$ANVS Most pos stock , it trades overnight and still goes down 5%.

0 · Reply

LionNoRichy Feb. 15 at 3:01 PM

$ANVS can someone give an unbiased recent update of the situation here

3 · Reply

doyoujetset Feb. 14 at 6:02 PM

$ANVS highest institutional accumulation to date. Take a look at the names and holdings⏳ https://fintel.io/so/us/anvs

2 · Reply

Madsj79 Feb. 14 at 2:41 AM

$ANVS Individuals with #AlzheimerDisease showing greater clinical impairment than predicted by tau burden are more likely to have copathology, including #TDP43 and #AlphaSynuclein, and experience faster decline. http://bit.ly/4aIBrBh

0 · Reply

xelroy Feb. 13 at 11:18 PM

$ANVS There is really nothing hilarious about people wanting a life changing treatment to fail. Disgusting!

1 · Reply

junkjar291 Feb. 13 at 4:22 PM

$ANVS Maria need to plan for trading on OTC in the fall...

2 · Reply

Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer's Disease

Dec 18, 2025, 4:35 PM EST - 2 months ago

Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients

Dec 16, 2025, 8:00 AM EST - 2 months ago

Annovis to Host Corporate Update Webinar on January 28, 2026

Dec 3, 2025, 8:00 AM EST - 2 months ago

Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group

Nov 24, 2025, 8:00 AM EST - 3 months ago

Annovis Announces Two Presentations at the CTAD 2025 Conference

Nov 18, 2025, 8:00 AM EST - 3 months ago

Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease Study

Nov 17, 2025, 1:07 PM EST - 3 months ago

Annovis Bio Stock Jumps As New Data Shows Buntanetap Halts Cognitive Decline In Parkinson's Patients

Nov 17, 2025, 8:00 AM EST - 3 months ago

Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's Patients

Nov 12, 2025, 8:00 AM EST - 3 months ago

Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results

Nov 6, 2025, 8:00 AM EST - 3 months ago

Annovis Achieves Significant Milestones and Sustains Strong Progress in Phase 3 Alzheimer's Program

Oct 27, 2025, 8:00 AM EDT - 4 months ago

Annovis Announces $3.4 Million Registered Direct Offering of Common Stock Priced At-the-Market under the NYSE Rules

Oct 15, 2025, 5:15 PM EDT - 4 months ago

Annovis Announces Closing of $6 Million Registered Direct Offering of Common Stock

Oct 10, 2025, 8:31 AM EDT - 4 months ago

Annovis Announces $6 Million Registered Direct Offering of Common Stock

Oct 9, 2025, 7:30 AM EDT - 4 months ago

Annovis Announces Novel Biomarker Data in Alzheimer's Patients Supporting Buntanetap's Potential as a Disease-Modifying Treatment

Sep 25, 2025, 7:30 AM EDT - 5 months ago

Annovis Appoints Mark Guerin as Chief Financial Officer

Sep 16, 2025, 7:30 AM EDT - 5 months ago

Annovis Reports Peer-Reviewed Publication Highlighting Pharmacokinetics of Novel Crystal Buntanetap

Sep 2, 2025, 8:00 AM EDT - 6 months ago

Annovis to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 12, 2025, 4:05 PM EDT - 6 months ago

Annovis Provides Corporate Updates and Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 8:00 AM EDT - 6 months ago

Annovis Completes Full Patent Transfer to Crystal Buntanetap

Jun 26, 2025, 8:00 AM EDT - 8 months ago

Annovis to Attend the AAIC 2025 with Four Poster Presentations

Jun 19, 2025, 6:30 AM EDT - 8 months ago

Annovis Announces NYSE Acceptance of Plan to Regain Listing Compliance

Jun 5, 2025, 8:00 AM EDT - 9 months ago

Annovis to Host Webinar and Live Q&A on June 24, 2025

May 13, 2025, 4:30 PM EDT - 10 months ago

Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results

Apr 29, 2025, 8:00 AM EDT - 10 months ago

Annovis Bio Appoints Hui Liu as Director of Biostatistics

Mar 27, 2025, 4:30 PM EDT - 11 months ago

Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE

Mar 25, 2025, 8:00 AM EDT - 11 months ago

Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program

Mar 21, 2025, 5:05 PM EDT - 11 months ago

Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Mar 11, 2025, 8:00 AM EDT - 1 year ago

Annovis Joins Experts at Drug Development Summit to Redefine Parkinson's Treatment

Feb 19, 2025, 8:30 AM EST - 1 year ago

Annovis to Host Patients' Live Forum on February 27, 2025

Feb 7, 2025, 8:00 AM EST - 1 year ago

Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Feb 5, 2025, 8:00 AM EST - 1 year ago

Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer's Disease

Feb 4, 2025, 4:31 PM EST - 1 year ago

Annovis Bio, Inc. Announces Closing of $21 Million Public Offering

Feb 3, 2025, 6:22 AM EST - 1 year ago

Annovis Bio, Inc. Announces Pricing of $21 Million Public Offering

Jan 31, 2025, 8:14 PM EST - 1 year ago

Annovis Bio, Inc. Announces Proposed Public Offering

Jan 14, 2025, 8:00 AM EST - 1 year ago

Annovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection

Dec 5, 2024, 8:30 AM EST - 1 year ago

Annovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today's Marketplace

Dec 4, 2024, 2:21 PM EST - 1 year ago

/C O R R E C T I O N -- Today's Marketplace/

Nov 25, 2024, 8:00 AM EST - 1 year ago

Annovis to Host Year-End Investor Webcast on December 11, 2024

Oct 31, 2024, 8:00 AM EDT - 1 year ago

IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Maria Maccecchini, CEO of Annovis Bio

Oct 15, 2024, 8:00 AM EDT - 1 year ago

FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer's Studies, Paving the Way to NDAs

Oct 3, 2024, 8:30 AM EDT - 1 year ago

Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative Diseases

Oct 2, 2024, 8:30 AM EDT - 1 year ago

Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential Future Breakthroughs in AD Space Through Innovative Combinations

Sep 5, 2024, 8:00 AM EDT - 1 year ago

Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment Conference

Aug 6, 2024, 8:00 AM EDT - 1 year ago

Annovis' Lead Compound Enhances Cognition Synergistically with GLP-1 Agonist

Jul 24, 2024, 8:00 AM EDT - 1 year ago

Annovis Bio Secures U.S. Patent for Treatment of Acute Traumatic Brain Injury with Buntanetap

Jul 2, 2024, 4:13 PM EDT - 1 year ago

Annovis stock more than doubled on Tuesday: what happened?

Jul 2, 2024, 1:57 PM EDT - 1 year ago

Annovis Bio's stock rockets 119% after reporting positive data in Parkinson's disease trial

Jun 26, 2024, 8:00 AM EDT - 1 year ago

Annovis Bio Files Patent for New Composition of Matter for Buntanetap

Jun 11, 2024, 8:00 AM EDT - 1 year ago

Annovis Bio's Buntanetap Found Safe and Effective in High-Risk Alzheimer's Patients

May 21, 2024, 7:30 AM EDT - 1 year ago

Annovis Announces New Publication in a Peer-Reviewed Journal

zshortcut Feb. 17 at 4:23 PM

$ANVS so what are we radio silence till 2027 now?

1 · Reply

RiskRecon Feb. 17 at 3:49 PM

$ANVS Annovis Bio develops Alzheimer's and Parkinson's therapies, with clinical-stage pipeline and binary catalysts.

0 · Reply

Veni_Vidi_Vici Feb. 17 at 2:07 PM

$ANVS I am no expert. Do your own due diligence. Understand the risks before investing in a clinical stage biotech. Annovis Followers on Stocktwits = 9,762

1 · Reply

Madsj79 Feb. 17 at 6:57 AM

1 · Reply

junkjar291 Feb. 17 at 4:12 AM

$ANVS Most pos stock , it trades overnight and still goes down 5%.

0 · Reply

LionNoRichy Feb. 15 at 3:01 PM

$ANVS can someone give an unbiased recent update of the situation here

3 · Reply

doyoujetset Feb. 14 at 6:02 PM

$ANVS highest institutional accumulation to date. Take a look at the names and holdings⏳ https://fintel.io/so/us/anvs

2 · Reply

Madsj79 Feb. 14 at 2:41 AM

0 · Reply

xelroy Feb. 13 at 11:18 PM

$ANVS There is really nothing hilarious about people wanting a life changing treatment to fail. Disgusting!

1 · Reply

junkjar291 Feb. 13 at 4:22 PM

$ANVS Maria need to plan for trading on OTC in the fall...

2 · Reply

dwayne09 Feb. 13 at 3:46 PM

$ANVS Just a matter if you want waite or not. Don't make it complicated.

0 · Reply

Martylevitt Feb. 13 at 3:00 PM

$ANVS https://x.com/itscarterhughes/status/2021661570062049454?s=20

0 · Reply

philtheclown Feb. 13 at 2:03 PM

$ANVS paid bashers, you clowns are irrelevant… keep working girls

1 · Reply

LionNoRichy Feb. 13 at 12:13 PM

$ANVS ... Missed the opportunity to leave in the $5.... If such a chance arise again I'll bail - this is horrendous

1 · Reply

ReturnOfEsquire Feb. 13 at 1:29 AM

$ANVS This guy likes his own messages...LOL. Talk about hilarious.

2 · Reply

cheesedonkey Feb. 12 at 11:43 PM

$ANVS No position until money is situated and full enrollment. Management has used up the benefit of the doubt. They're lucky the scientific reasoning is sound. Back to the shadows.

3 · Reply

EmotionlessRobot Feb. 12 at 9:10 PM

$ANVS Cash remains an issue. Good but expected news today but I wouldn't necessarily overlook it. The competitor's therapies cause brain bleeds, keep that in mind. If this drug works, the safety profile, combined with it being a simple pill, further derisks it as an acquisition or partnership target. We need to see some movement on cash soon. I will say the options granting last year is intriguing.

0 · Reply

philtheclown Feb. 12 at 5:07 PM

$ANVS paid bashing dummies on this site are hilarious

0 · Reply

ReturnOfEsquire Feb. 12 at 4:03 PM

$ANVS AI's take on slower than expected enrollment..

3 · Reply

LittleShins69 Feb. 12 at 3:18 PM

$ANVS another 5k shares at open.. Great release td

0 · Reply

Smuttlee Feb. 12 at 3:16 PM

$ANVS 26,5 million OS, $62.8 million market cap on a company that is very likely worth $1BILLION plus! Late stage drug for both Alzheimer’s and Parkinson’s with proven safety results and significant data proving that the company has a game changing drug for 2 terrible diseases. Time to consider when the investment community opens up its eyes and pile into this tremendous opportunity. Possibly approved by FDA in 18 months or less! Can’t catch the ride if it’s already left the station. Jmo

0 · Reply

zshortcut Feb. 12 at 2:41 PM

$ANVS is that why enrollment didn't really progress because they where under review?

3 · Reply

Market Cap	62.81M
Revenue (ttm)	0.00
Net Income (ttm)	-24.59M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	339,634
Avg Vol	532,868
Day's Range	N/A - N/A
Shares Out	26.50M
Stochastic %K	22%
Beta	1.52
Analysts	Strong Sell
Price Target	$11.67